middle.news
Imugene Raises A$20 Million to Accelerate Cancer Immunotherapy Trials
8:19am on Wednesday 29th of January, 2025 AEDT
•
Healthcare
Read Story
Imugene Raises A$20 Million to Accelerate Cancer Immunotherapy Trials
8:19am on Wednesday 29th of January, 2025 AEDT
Key Points
A$20 million received from convertible notes issuance to CVI Investments
First tranche of a planned A$46 million capital raising
Funds earmarked for clinical trials of azer-cel, onCARlytics, and VAXINIA
Convertible notes feature zero-coupon, five-year maturity, and conversion premium
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE